CX Institutional Acquires 12,964 Shares of Cencora, Inc. $COR

CX Institutional raised its holdings in shares of Cencora, Inc. (NYSE:COR) by 132.3% during the third quarter, according to its most recent filing with the SEC. The firm owned 22,763 shares of the company’s stock after purchasing an additional 12,964 shares during the period. CX Institutional’s holdings in Cencora were worth $7,114,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of COR. Security Financial Services INC. increased its holdings in Cencora by 2.6% during the third quarter. Security Financial Services INC. now owns 1,325 shares of the company’s stock valued at $414,000 after buying an additional 33 shares during the period. Atlantic Edge Private Wealth Management LLC boosted its position in Cencora by 70.0% during the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after acquiring an additional 35 shares in the last quarter. Grove Bank & Trust increased its holdings in shares of Cencora by 4.3% in the 2nd quarter. Grove Bank & Trust now owns 879 shares of the company’s stock valued at $264,000 after acquiring an additional 36 shares during the period. Quadcap Wealth Management LLC raised its position in shares of Cencora by 1.5% in the 2nd quarter. Quadcap Wealth Management LLC now owns 2,409 shares of the company’s stock worth $722,000 after acquiring an additional 36 shares in the last quarter. Finally, U.S. Capital Wealth Advisors LLC raised its position in shares of Cencora by 0.4% in the 2nd quarter. U.S. Capital Wealth Advisors LLC now owns 8,547 shares of the company’s stock worth $2,563,000 after acquiring an additional 38 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on COR. Weiss Ratings reiterated a “hold (c+)” rating on shares of Cencora in a research note on Monday, December 29th. UBS Group lifted their price objective on shares of Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Evercore ISI set a $400.00 target price on shares of Cencora and gave the company an “outperform” rating in a research report on Thursday, November 6th. Barclays assumed coverage on shares of Cencora in a research note on Monday, December 8th. They issued an “overweight” rating and a $400.00 target price for the company. Finally, TD Cowen upped their price target on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, Cencora currently has an average rating of “Moderate Buy” and an average price target of $379.50.

Insider Transactions at Cencora

In related news, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the completion of the sale, the chief executive officer owned 37,940 shares of the company’s stock, valued at $12,398,792. The trade was a 11.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $342.10, for a total value of $1,146,377.10. Following the completion of the sale, the executive vice president owned 23,891 shares in the company, valued at approximately $8,173,111.10. This represents a 12.30% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 20,317 shares of company stock worth $7,009,260 over the last three months. 10.80% of the stock is currently owned by insiders.

Cencora Trading Down 1.6%

Shares of Cencora stock opened at $340.54 on Thursday. The firm’s 50 day simple moving average is $350.04 and its two-hundred day simple moving average is $317.68. The firm has a market capitalization of $66.06 billion, a price-to-earnings ratio of 42.83, a PEG ratio of 1.65 and a beta of 0.66. Cencora, Inc. has a 12-month low of $233.61 and a 12-month high of $377.54. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The firm had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. During the same period in the previous year, the company earned $3.34 earnings per share. The business’s quarterly revenue was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were issued a $0.60 dividend. This is a boost from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, November 14th. Cencora’s dividend payout ratio is currently 30.19%.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.